NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM